Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction.
about
Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitisInfliximab-Related Infusion Reactions: Systematic ReviewSAMP1/YitFc mouse strain: a spontaneous model of Crohn's disease-like ileitis.Low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis.Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.Overview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases.Current therapy of ulcerative colitis in children.Infliximab in the treatment of Crohn's disease.Polypharmacy and Crohn's disease.Managing complicated Crohn's disease in children and adolescents.Infliximab therapy for pediatric Crohn's disease.Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis.Balancing and communicating the risks and benefits of biologics in pediatric inflammatory bowel diseaseUse of immunomodulators and biologic therapies in children with inflammatory bowel disease.A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease.Acute infusion reactions induced by monoclonal antibody therapy.Exploring the differential diagnosis of joint complaints in pediatric patients with inflammatory bowel disease.Antitumor necrosis factor treatment for pediatric inflammatory bowel disease.Infliximab for the treatment of pediatric ulcerative colitis.Formation, clearance, deposition, pathogenicity, and identification of biopharmaceutical-related immune complexes: review and case studies.Premedication Use in Preventing Acute Infliximab Infusion Reactions in Patients with Inflammatory Bowel Disease: A Single Center Cohort Study.Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease.The efficacy and safety of reinstitution of tocilizumab in patients with relapsed active rheumatoid arthritis after long-term withdrawal of tocilizumab: retreatment of patients with rheumatoid arthritis with novel anti-IL-6 receptor antibody after aBiologics in dermatology: adverse effects.Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy.Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium.Safety and tolerability of infliximab therapy: suggestions and criticisms based on wide clinical experience.Serum sickness-like reaction due to Infliximab reintroduction during pregnancy.Genetic associations with adverse events from anti-tumor necrosis factor therapy in inflammatory bowel disease patients.Durability of infliximab in Crohn's disease: a single-center experience.Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease.Clinical and radiologic analysis of on-demand use of etanercept for disease flares in patients with rheumatoid arthritis for 2 years: The RESUME study: A case-control study
P2860
Q24245033-F33A5DE0-CD40-4579-B0F0-A682954A2C97Q27013835-0A866961-9399-429B-A70F-AF342FADCFFFQ30423660-1C8E9667-D546-4A12-90EC-3E16FE9155F5Q34654104-54D2F512-009B-4851-9151-4F7D69C035CCQ35030557-A55DD866-D8CD-4203-8E49-7A3CF778C78DQ35116177-B0A340BE-9D08-4833-BFBD-A9010343CBFCQ35609674-CFF4E576-C2A3-4C17-93F5-CAAF75DA070AQ35919228-72F40753-0A85-40FA-ABC8-A50285062C1DQ36120936-849B213F-642F-409D-8763-1050F92ACD64Q36331225-F4247A40-BD42-4008-AD1A-D3528B377ED1Q37012073-0D05A3BE-CEA9-4C49-9B7A-911D5FD9E4EAQ37033874-60753F75-2674-4DD1-B511-D8C19A890081Q37609746-8633E687-B4AD-4F48-90A3-38260F1C73E4Q37769253-D76FBEB5-E4D3-4434-A34B-061BC2ABB952Q37814549-1E0AA691-442A-4AB1-9F05-C91F7818A9AFQ37821495-FF615575-A304-4D76-9BE0-866FE08BDCEFQ37836510-BACB3052-B357-43B0-8233-90F9B18A2715Q37936394-955AF367-777F-475C-9C93-A65EBA2E72BDQ38067127-3F04D686-EB9E-4C3A-9F42-25920DF80687Q38202541-1BD5F346-041F-4E0F-B08C-C5CEA48994FBQ38637766-C5EC0383-9662-4C75-9490-44C8ECD16F5BQ38673082-F68B56A9-5596-42AC-BE8A-65C05EE9A871Q39113455-3C932214-CFB3-4719-80CD-5A5889A753AAQ41120913-C4366EFC-BEC4-4D9D-A048-FE6F086F079DQ46234832-8F9FFCC6-E8B9-402C-BBE3-8BACD9A589DFQ46469250-9DC4180C-84E2-46F4-B5D5-0F58DF71D042Q46545377-420E133E-AA63-4C46-B52D-5B000EDE5AF4Q46935733-3179BB92-2753-4E5D-9020-B66A0DEB5A03Q47159585-36679CBF-E2AD-45EB-9A72-FBB89CB77E8EQ47744808-069738B0-DEF5-4DB0-86C6-9905F436B9E4Q51036254-A06A7A8F-7278-4192-87AF-4119463EDFF9Q58703890-E0299C59-EB0C-4D32-917E-D9D6A3143E63
P2860
Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Infliximab retreatment in adul ...... ayed severe systemic reaction.
@en
type
label
Infliximab retreatment in adul ...... ayed severe systemic reaction.
@en
prefLabel
Infliximab retreatment in adul ...... ayed severe systemic reaction.
@en
P2093
P2860
P1476
Infliximab retreatment in adul ...... ayed severe systemic reaction.
@en
P2093
Alfonso Martinez
David G Binion
Devang Prajapati
Jeanne Emmons
Joseph P Kim
Kevin J Kelly
Kia Saeian
Michael B Levy
Sotirios Vasilopoulos
Subra Kugathasan
P2860
P304
P356
10.1111/J.1572-0241.2002.05784.X
P407
P577
2002-06-01T00:00:00Z